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A B S T R A C T
Background
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are syndromes of severe respiratory failure that are associated
with substantial mortality and morbidity. Artifical ventilatory support is commonly required and may exacerbate lung injury. Partial
liquid ventilation (PLV) has been proposed as a less injurious form of ventilatory support for these patients. Although PLV has been
shown to improve gas exchange and to reduce inflammation in experimental models of ALI, a previous systematic review did not find
any evidence to support or refute its use in humans with ALI and ARDS.
Objectives
The primary objective of this review was to assess whether PLV reduced mortality (at 28 d, at discharge from the intensive care unit
(ICU), at discharge from hospital and at one, two and five years) in adults with ALI or ARDS when compared with conventional
ventilatory support.
Secondary objectives were to determine howPLV comparedwith conventional ventilationwith regard to duration of invasivemechanical
ventilation, duration of respiratory support, duration of oxygen therapy, length of ICU stay, length of hospital stay, incidence of
infection, long-term cognitive impairment, long-term health related quality of life, long- term lung function, long-term morbidity
costs and adverse events. The following adverse events were considered: hypoxia (arterial PO2 <80 mm Hg), pneumothorax (any air
leak into the pleural space requiring therapeutic intervention), hypotension (systolic blood pressure < 90 mm Hg sustained for longer
than two minutes or requiring treatment with fluids or vasoactive drugs), bradycardia (heart rate < 50 beats per minute sustained for
longer than one minute or requiring therapeutic intervention) and cardiac arrest (absence of effective cardiac output).
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Search methods
In this updated review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL Issue 10, 2012, in The Cochrane
Library; MEDLINE (Ovid SP, 1966 to November 2012); EMBASE (Ovid SP, 1980 to November 2012) and CINAHL (EBSCO-
host,1982 to November 2012) for published studies. In our original review, we searched until May 2004.
Grey literature was identified by searching conference proceedings and trial registries and by contacting experts in the field.
Selection criteria
As in the original review, review authors selected randomized controlled trials that compared PLV with other forms of ventilation in
adults (16 y of age or older) with ALI or ARDS, reporting one or more of the following: mortality; duration of mechanical ventilation,
respiratory support, oxygen therapy, stay in the intensive care unit or stay in hospital; infection; long-term cognitive impairment or
health-related quality of life; long-term lung function or cost.
Data collection and analysis
Two review authors independently evaluated the quality of the relevant studies and extracted the data from included studies.
Main results
In this updated review, one new eligible study was identified and included, yielding a total of two eligible studies (including a combined
total of 401 participants). Of those 401 participants, 170 received ’high’-dose partial liquid ventilation (i.e. a mean dose of at least 20
mL/kg), 99 received ’low-dose’ partial liquid ventilation (i.e. a dose of 10 mL/kg) and 132 received conventional mechanical ventilation
(CMV). Pooled estimates of effect were calculated for all those who received ’high’-dose PLV versus conventional ventilation. No
evidence indicated that ’high’-dose PLV either reduced mortality at 28 d (risk ratio (RR) 1.21, 95% confidence interval (CI) 0.79 to
1.85, P = 0.37) or increased the number of days free of CMV at 28 d (mean difference (MD) -2.24, 95% CI -4.71 to 0.23, P = 0.08).
The pooled estimate of effect for bradycardia in those who received PLV was significantly greater than in those who received CMV
(RR 2.51, 95% CI 1.31 to 4.81, P = 0.005). Pooled estimates of effect for the following adverse events hypoxia, pneumothorax,
hypotension and cardiac arrest all showed a nonsignificant trend towards a higher occurrence of these events in those treated with
PLV. Because neither eligible study addressed morbidity or mortality beyond 28 d, it was not possible to determine the effect of PLV
on these outcomes.
Authors’ conclusions
No evidence supports the use of PLV in ALI or ARDS; some evidence suggests an increased risk of adverse events associated with its
use.
P L A I N L A N G U A G E S U M M A R Y
No evidence of benefit of partial liquid ventilation in adults with acute lung injury and some evidence of increased risk associated
with its use
Seriously ill adults can get a severe lung disease called acute lung injury or acute respiratory distress syndrome, which stops enough oxygen
from getting into the blood. About half of these patients die, and for those who survive, it can take several years to get back to near
normal.
At the height of their illness, many of these patients are unable to breathe properly and need the assistance of a breathing machine
called a ventilator, which pushes gas into the lungs under pressure through a process called artifical ventilation. Artifical ventilation can
cause further damage to the lungs. The need to support breathing for these patients, while avoiding further lung damage, has led to a
search for gentler types of ventilation.
One such gentler type of ventilation is called partial liquid ventilation. It uses a special liquid called perfluorocarbon instead of the gas
used by traditional ventilators.
The purpose of this systematic review was to determine whether patients with acute lung injury who received partial liquid ventilation
were less likely to die or were more likely to recover completely than those who received traditional gas ventilation.
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To provide the best possible answer to this question, this review was conducted in a special preplanned way with the intention of
putting together the results of all selected studies to produce an overall measure of the value of partial liquid ventilation. Two eligible
studies (including a total of 401 participants) were found, and a comparison was made between those who received similar doses of
perfluorocarbon and those who received traditional ventilation. No evidence indicated that partial liquid ventilation reduced the risk
of death or the duration of artifical ventilation, and some evidence suggested that it may increase the risk of complications, including
low blood oxygen levels, low heart rate, low blood pressure, air leakage from the lungs and cardiac collapse.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Partial liquid ventilation compared with conventional mechanical ventilation for acute lung injury and acute respiratory distress syndrome
Patient or population: mechanically ventilated participants with acute lung injury and acute respiratory distress syndrome
Settings: Intensive care in Europe and North America
Intervention: Partial liquid ventilation
Comparison: Conventilation mechanical ventilation
Outcomes Illustrative comparative risks* (95% CI) Risk ratio
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Conventional mechani-
cal ventilation
Partial liquid ventilation
28 d mortality 1.8 per 1000 2.18 per 1000 1.21
(0.79 to 1.85)
302
(2)
⊕⊕©©
low1
Number of days free
of mechanical ventila-
tion in a 28 d period
The number of days free
of mechanical ventilation
in the control groups dur-
ing a 28 d period ranged
from 3.7 to 22.3 d
The mean number of days
free of mechanical venti-
lation in a 28 d period was
2.24 (4.71 to 0.23) d less
in the PLV group than in
the CMV group
302
(2)
⊕⊕©©
low1
Adverse events
Hypoxia 2.4 per 1000 4.2 per 1000 1.77
(0.97 to 3.24)
302
(2)
⊕⊕©©
low1
Pneumothorax 1.0 per 1000 2.0 per 1000 2.06
(0.71 to 5.95)
302
(2)
⊕⊕©©
low1
Hypotension 2.2 per 1000 3.0 per 1000 1.38
(0.87 to 2.19)
302
(2)
⊕⊕©©
low1
4
P
a
rtia
l
liq
u
id
v
e
n
tila
tio
n
fo
r
p
re
v
e
n
tin
g
d
e
a
th
a
n
d
m
o
rb
id
ity
in
a
d
u
lts
w
ith
a
c
u
te
lu
n
g
in
ju
r
y
a
n
d
a
c
u
te
re
sp
ira
to
ry
d
istre
ss
sy
n
d
ro
m
e
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
3
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Bradycardia 0.8 per 1000 2.0 per 1000 2.51
(1.31 to 4.81)
302
(2)
⊕⊕©©
low1
Cardiac arrest 0.5 per 1000 0.7 per 1000 1.31
(0.56 to 3.04)
302
(2)
⊕⊕©©
low1
*The basis for the assumed risk (e.g. the mean control group risk across included studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1.The ’low’ quality grade was assigned on the basis that only two studies were eligible for inclusion in this meta-analysis, limiting the
quantity of data available for analysis, and based on the fact that both studies excluded those with severe nonpulmonary organ
dysfunction, limiting the generalizability of these results.
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B A C K G R O U N D
Description of the condition
Acute lung injury (ALI) and its more severe form, acute respira-
tory distress syndrome (ARDS), are characterized by the devel-
opment of noncardiogenic pulmonary oedema and hypoxaemia
(Bernard 1994). By definition, it is a secondary illness, occurring
in response to an initial primary illness or insult, including severe
pneumonia, pancreatitis, sepsis, trauma, shock and massive blood
transfusion (Bernard 1994; Raneiri 2012). Since it was first de-
scribed more than four decades ago, ALI remains a major cause of
acute respiratory failure, accounts for in excess of 200,000 inten-
sive care unit (ICU) admissions annually and requires more than
3.5 million d of inpatient care per year. It carries a mortality rate of
35% to 44% and substantial survivor morbidity (Ashbaugh 1967;
Herridge 2011; Rubenfeld 2005; Rubenfeld 2007).
Pathophysiological changes seen in ALI include endothelial in-
flammation, increasedmicrovascular permeability, alveolar and in-
terstitial oedema and de-activation of surfactant, leading to atelec-
tasis, ventilation/perfusion mismatch and reduced lung compli-
ance (Matthay 2011; Ware 2000). The resultant hypoxaemia and
increased work of breathing, superimposed on the initial causative
acute illness, mean that many patients are unable to maintain
effective spontaneous breathing and require artificial ventilatory
support (Tobin 2001).
Mechanical ventilation can exacerbate lung injury by causing ven-
tilator-induced lung injury a constellation of structural damage
caused by volume and pressure changes and biotrauma due to acti-
vation of inflammatory cascades (de Prost 2011). This has led to a
search for less traumatic ways of providing respiratory support for
these patients. Lung protective ventilation strategies, limiting tidal
volumes and pressures, have been shown to improve outcomes
(ARDSNetwork 2000).Other techniques that have been explored
include the use of nitric oxide, prone positioning, high-frequency
oscillatory ventilation and extracorporal membrane oxygenation
(ECMO) (Adhikari 2007; Derdak 2002; Taccone 2009; Combes
2012). To date, none of these interventions have been shown to
confer a substantial survival benefit in unselected participants with
ALI (Adhikari 2007;Derdak 2002; Taccone 2009; Combes 2012).
Description of the intervention
Partial liquid ventilation has been proposed as a possibly benefi-
cial form of ventilatory support in ALI (Wiedemann 2000). Using
liquids to facilitate gas exchange was first proposed in the 1960s,
when Kylstra and colleagues showed that mammals could breathe
in a liquidmedium (Kylstra 1962). Initial experiments using saline
required hyperbaric conditions to dissolve enough oxygen in solu-
tion (Kylstra 1962). This led to a search for fluids that could carry
large amounts of oxygen and carbon dioxide at atmospheric pres-
sure. Only silicone oils and perfluorocarbons were found to have
these properties, and as silicone oils proved toxic, only perfluoro-
carbons were investigated further (Clark 1966). These synthetic
fluorinated hydrocarbons are nontoxic, have an oxygen-carrying
capacity three times that of blood and low surface tension and are
chemically and metabolically inert, being eliminated by evapora-
tion (Kaisers 2003).
Initial studies of liquid ventilation involved filling the lungs com-
pletely with liquid and administering a liquid tidal volume. This
technique, which is called total liquid ventilation, necessitates the
use of a specially designed ventilator (Kaisers 2003). It remains
largely experimental.
In 1991, Fuhrman and colleagues described an animal experi-
ment in which they filled the lungs to functional residual capac-
ity with perfluorocarbon (PFC) and provided a gaseous tidal vol-
ume (Fuhrman 1991). This technique, in which the lungs are par-
tially filled with liquid, is called partial liquid ventilation (PLV)
(Kaisers 2003). It can be used with commercially available ven-
tilators and has been the focus of much study in both animals
and humans (Hernan 1996;Hirschl 1995 Effects of interventions;
Hirschl 1996; Wiedemann 2000).
How the intervention might work
The rationale for the use of PLV in ALI centres on the physi-
cal properties of perfluorocarbons, which make them particularly
useful in the context of increased surface tension at the air-gas
interface, which occurs in this condition (Kaisers 2003; Matthay
2011).
The very low surface tension of PFCs gives them surfactant-like
properties, thereby improving lung compliance. Twice as dense as
water, they gravitate to dependent regions of the lung, reopen-
ing collapsed alveoli and acting as liquid positive end-expiratory
pressure (PEEP) (Davies 1999; Kaisers 2003). Perfluorocarbons
are thought to improve ventilation/perfusion matching by com-
pressing blood vessels (through PFC-filled alveoli) in dependent
regions of the lung, with consequent diversion of blood flow to the
gas-filled alveoli in nondependent regions (Davies 1999; Kaisers
2003). The kinetic effects of liquid ventilation may assist with
mobilization of debris and secretions (Tawfic 2010). Aside from
their physical properties, animal studies have shown that PFCs
have anti-inflammatory effects that may reduce lung injury and
inflammation (Pakulla 2004: Zhu 2010).
Why it is important to do this review
It has been eight years since the original review of this topic was
conducted. Since then, important advances have been made in
our approach to ventilatory support of patients with ALI (ARDS
Network 2000), and awareness has increased regarding the impor-
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tance of quality in the reporting of randomized controlled trials
(RCTs) (Dechartres 2011; Falagas 2009).
O B J E C T I V E S
The primary objective of this review was to assess whether PLV
reducedmortality (at 28d, at discharge from the intensive care unit
(ICU), at discharge from hospital and at one, two and five years)
in adults with ALI or ARDS when compared with conventional
ventilatory support.
Secondary objectives were to determine how PLV compared with
conventional ventilation with regard to duration of invasive me-
chanical ventilation, duration of respiratory support, duration of
oxygen therapy, length of ICU stay, length of hospital stay, in-
cidence of infection,long-term cognitive impairment, long- term
health related quality of life, long-term lung function, long-term
morbidity costs and adverse events. The following adverse events
were considered: hypoxia (arterial PO2 < 80 mmHg), pneumoth-
orax (any air leak into the pleural space requiring therapeutic in-
tervention), hypotension (systolic blood pressure < 90 mm Hg
sustained for longer than two minutes or requiring treatment with
fluids or vasoactive drugs), bradycardia (heart rate < 50 beats per
minute sustained for longer than one minute or requiring thera-
peutic intervention) and cardiac arrest (absence of effective cardiac
output).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs.
Types of participants
We included mechanically ventilated adults with ALI ± ARDS.
We defined adults as persons aged 16 y or older.
ALI and ARDS were defined according to American European
Consensus Conference (AECC) criteria (i.e. the definition in use
until 2012).
Definition of ALI (Bernard 1994):
• Acute onset of respiratory failure;
• Bilateral opacities on chest x-ray (CXR) consistent with
pulmonary oedema;
• Pulmonary artery wedge pressure < 18 mm Hg or no
clinical evidence of raised left atrial pressure; and
• Partial pressure of oxygen in the blood (PaO2)/fraction of
inspired oxygen (FiO2) ratio ≤300 mm Hg.
Definition of ARDS (Bernard 1994):
• Acute onset of respiratory failure;
• Bilateral opacities on CXR consistent with pulmonary
oedema;
• Pulmonary artery wedge pressure < 18 mm Hg or no
clinical evidence of raised left atrial pressure; and
• PaO2/FiO2 ≤ 200 mm Hg.
Types of interventions
PLV compared with other forms of ventilatory management with-
out the use of PFC.
Types of outcome measures
One or more of the following outcomes must be reported.
Primary outcomes
• Mortality (at 28 d, at discharge from ICU, at discharge
from hospital and at one, two and five years).
Secondary outcomes
• Duration of invasive mechanical ventilation (i.e. duration
of ventilatory support delivered via endotracheal tube or
tracheostomy).
• Duration of respiratory support (i.e. duration of any form
of artifical support with ventilation, including both invasive
ventilation as defined above and noninvasive ventilation
delivered via face mask, nasal mask or hood.
• Duration of oxygen therapy.
• Length of stay in the ICU.
• Length of stay in hospital.
• Infection (sepsis, pneumonia).
• Long-term cognitive impairment.
• Long-term health-related quality of life.
• Long-term lung function.
• Long-term morbidity costs.
• Adverse events.
Search methods for identification of studies
Electronic searches
In this updated review, we searched the Cochrane Central Register
of Controlled Trials (CENTRAL, Issue 10, 2012, in The Cochrane
Library; Appendix 1); MEDLINE (Ovid SP, 1966 to Novem-
ber 2012; Appendix 2); EMBASE (Ovid SP, 1980 to November
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2012; Appendix 3) and CINAHL (EBSCOhost, 1982 to Novem-
ber 2012; Appendix 4). In the previous version (Davies 2004), the
databases were searched to May 2004.
We identified RCTs of PLV in ALI or ARDS fromMEDLINE us-
ing the Medical Subject Heading (MeSH) ’RESPIRATORY DIS-
TRESS SYNDROME, ADULT’ or the text words ’ARDS’, ’ALI’
or ’acute lung injury’ and the MeSH heading ’FLUOROCAR-
BONS’ or the text word ’partial liquid ventilation’.
Searching other resources
We searched the proceedings of major annual Critical Care con-
ferences (i.e. American Thoracic Society, International Sympo-
sium on Intensive Care and EmergencyMedicine, Society of Crit-
ical Care Medicine, European Society of Intensive Care Medicine,
American College of Chest Physicans, Intensive Care Society UK
and Canadian Critical Forum).
We searched the metaRegister of Controlled Trials for relevant
ongoing trials using the search terms ’liquid ventilation’, ’partial
liquid ventilation’, ’liquid ventilation’, ’acute respiratory distress
syndrome’, ’acute lung injury’, ’ALI’, ’ARDS’ and ’perfluorocar-
bon’.
Finally we contacted experts in the field of PLV research to identify
unpublished studies.
Data collection and analysis
Selection of studies
Two review authors (IMG and AS) independently selected studies
according to the following process. We assessed each title and ab-
stract retrieved by the search strategy to determine whether they
met the eligibility criteria for inclusion. We excluded studies that
were clearly ineligible (animal studies and those addressing inter-
ventions other than liquid ventilation) at this stage. For all other
studies, we examined full-text versions to determine eligibility.We
assessed methodological quality using the criteria detailed above,
and the study was excluded or accepted for inclusion. We resolved
any discrepancies by discussion between these two review authors.
One review author (IMG) was responsible for contacting primary
study authors when additional details were required for determi-
nation of study eligibility and quality.
Data extraction and management
A comprehensive data extraction form was designed by one review
author (IMG), using all items in the checklist recommended in
Section 7 of theCochrane Handbook of Systematic Reviews for Inter-
ventions (Higgins 2011). Two review authors (IMG and AS) inde-
pendently extracted data. We entered data initially onto the data
extraction form and then into the appropriate fields in RevMan.
RevMan entries were checked against the primary study report by
two review authors (IMG and AS).
Assessment of risk of bias in included studies
The risk of bias in included studies was assessed independently by
two review authors (IMG, AS), using the Cochrane Collaboration
tool for assessing risk of bias, as described in Section 8 of the
CochraneHandbook of Systematic Reviews for Interventions (Higgins
2011). We resolved any discrepancies by discussion between the
assessing review authors. For each included primary study, bias
was assessed in the domains detailed below. For each domain,
we determined the risk of bias as ’high’, ’low’ or ’unclear’, and
each judgement was supported by direct quotes from the primary
reports, where applicable.
Random sequence generation
• Probably done/low risk: where the study report described a
random method of sequence generation.
• Probably not done/high risk: where the study report did not
describe a random method of sequence generation.
• Uncertain/unclear risk: where the study report did not
provide enough information to reveal whether or not a random
method was used.
Allocation concealment
• Probably done/low risk: where the study report described a
centralized method of intervention allocation or a method by
which investigators could not feasibly foresee the treatment
assignments of individual participants.
• Probably not done/high risk: where the study report did not
describe a centralized method of intervention allocation or a
method by which investigators could not feasibly foresee the
treatment assignments of individual participants.
• Uncertain/unclear risk: where the study report did not
provide enough information to reveal whether or not the method
used was likely to ensure allocation concealment.
Performance bias
• Blinding of participants and personnel.
• Probably done/low risk: where the study report described
blinding of participants and key study personnel.
• Probably not done/low risk: where the study report did not
describe a blinded method, or blinding was incomplete but
measures were taken to ensure and determine equality of
ancillary treatment between groups.
• Probably not done/ high risk: where the study report did
not describe a blinded method, or blinding was incomplete and
measures were not taken to ensure and determine equality of
ancillary treatment between groups.
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• Probably not done/ unclear risk: where the study report did
not describe a blinded method, or blinding was incomplete and
the authors did not describe measures taken to ensure and
determine equality of ancillary treatment between groups.
Detection bias
• Blinding of outcome assessment.
• Probably done/low risk: where the study report described
blinding of participants and key study personnel.
• Probably not done/low risk: where the study report did not
describe a blinded method, or blinding was incomplete but
outcome measures addressed were objective.
• Probably not done/ high risk: where the study report did
not describe a blinded method, or blinding was incomplete and
outcome measures addressed were subjective.
• Probably not done/ unclear risk: where the study report
does not provide enough information to reveal the extent or
adequacy of blinding or its likely impact on outcome assessment.
Attrition bias
• Incomplete outcomes data.
• Low risk: no missing outcome data for prespecified
outcomes, or missing data equally balanced between groups, or
reasons for missing data unlikely to be related to the intervention
or to the outcome or unlikely to have a significant influence on
the effect estimate or missing data dealt with by using
appropriate imputation methods.
• High risk: missing data for prespecified outcomes and any
of the following missing data unequally balanced between
groups, or reasons for missing data likely to be related to the
intervention or to the outcome or likely to have a significant
influence on the effect estimate or missing data not dealt with by
using appropriate imputation methods.
• Unclear risk: the study report does not provide enough
information to reveal the extent of missing data or the influence
of missing data on study results.
Reporting bias
• Outcome reporting bias.
• Low risk: all prespecified outcomes reported completely.
• High risk: one or more prespecified outcomes not reported
or reported incompletely.
• Unclear risk: not enough information to reveal the
adequacy of outcome reporting.
Other bias
• Low risk: no other potential source of bias identified.
• High risk: other potential sources of bias identified.
• Unclear risk: report not complete enough to allow accurate
determination of the presence or absence of other sources of bias.
Measures of treatment effect
We performed the meta-analyses using Review Manager software
(RevMan 5.1). We included two eligible studies and compared all
participants who received similar dosages of perflurocarbon with
those who received conventional mechanical ventilation. We used
a random-effects model and calculated categorical outcomes as
risk ratios (RRs) and continuous outcomes as mean differences
(MDs), with 95% confidence intervals (CIs) for both.
Unit of analysis issues
None identified.
Dealing with missing data
For all missing data, we planned to determine whether data were
’missing completely at random’, missing at random’ or ’missing
not at random’. Data were judged to be ’missing completely at
random’ and ’missing at random’ if the reasons the data were miss-
ing were ’highly unlikely’ and ’unlikely’, respectively, to be related
to the intervention or the outcome being addressed. Data were
judged to be ’missing not at random’ if the reason the data were
missing was ’likely’ related to the intervention or to the outcomes
being addressed. For data judged to be ’missing not at random’,
we planned to determine the degree of influence this was likely to
have on the effect estimates from the study and on the adequacy
of statistical measures used to take account of the missing data.
Where appropriate alternative analyses were used to take account
of missing data, we planned to use effect estimates from those
analyses to contribute to our pooled estimates of effect.
We planned to discuss all available details regarding missing data
and the likely impact of this on the findings of this review, and,
if appropriate, to conduct a sensitivity analysis to evaluate the po-
tential impact of incomplete outcome data on the pooled estimate
of effect.
Assessment of heterogeneity
Included studies were assessed for clinical heterogeneity by com-
paring the following factors: study participants, setting, interven-
tions and ancillary treatments. Methodological heterogeneity was
assessed by determining and comparing the risk of bias in included
studies.
Where included studies were adequately homogenous in terms of
clinical and methodological aspects, statistical heterogeneity was
assessed by performing a visual inspection of forest plots and the
Chi2 test (assessing the P value) and by calculating the I2 statistic.
A P value less than 0.10 and I2 in excess of 50% were taken as
indicative of significant heterogeneity.
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Assessment of reporting biases
Todetermine the presence or absence of reporting bias, we planned
to examine funnel plots for each meta-analysis that included ten
or more studies to determine if they were symmetrical. Where
plots were visually asymmetrical, the meta-analysis was judged to
be potentially biased because of small study effects or reporting
bias.
Data synthesis
It was planned that a meta-analysis would be performed if all of
the following conditions were met:
• No significant clinical or statistical heterogeneity of the
included studies;
• Inclusion of at least two eligible studies deemed to have low
individual risks of bias; and
• No substantial reporting bias.
Subgroup analysis and investigation of heterogeneity
If adequate numbers of eligible studies were identified (at least
three), we planned to perform subgroup analyses to determine
whether the results differ by:
Population:
• Age;
• Severity of overall illness (e.g. Acute Physiology and
Chronic Health Evaluation (APACHE) score or Simplified
Acute Physiology Score (SAPS)) or severity of ALI or ARDS; and
• Aetiology of ALI or ARDS (e.g. septicaemia, pneumonia,
trauma, burns).
Mortality and other outcomes have been shown to vary by the age
of the patient, the initial severity of ALI or ARDS or of the patient’s
condition (e.g. by APACHE score) and the underlying cause of
ALI or ARDS (Monchi 1998; Suntharalingam 2001;Ware 2000).
Intervention:
• Initial amount or dose of perflurocarbon (PFC);
• Whether continuous PLV or intermittent doses of PFC are
used; and
• Type of PFC (e.g. perflubron, Rimar).
The optimal dose of PFC that should be usedwhenPLV is initiated
is unknown. Variations in the technique of PLV may also include
giving an initial dose of PFC with or without further top-up doses
to maintain partial filling of the lungs. Various types of PFC with
different physical and chemical properties may be used (Davies
1999).
Co-interventions used in addition to PLV:
• Inhaled nitric oxide;
• Surfactant;
• The prone position; and
• High-frequency ventilation.
Whilst the mainstay of treatment for ALI or ARDS is mechanical
ventilation, additional therapies have been considered, and some
of these have been subjected to RCTs. Adjuncts to mechanical
ventilation have included inhaled nitric oxide, endogenous surfac-
tant, prone positioning and high-frequency ventilation (Conner
2000); all can be used in conjunction with PLV.
Sensitivity analysis
If adequate numbers of eligible studies of good methodological
quality were identified (three or more), we planned to conduct the
following sensitivity analyses to test how robust our findings are
under the following conditions:
• Analysis excluding all studies considered to be at high or
unclear risk of bias; and
• Analysis excluding studies with missing data considered to
be ’missing not at random’.
R E S U L T S
Description of studies
Results of the search
In combining our original searches from the period 1966 to May
2004with updated searches covering the period fromMay 2004 to
November 2012, we retrieved a total of 749 citations. We reviewed
the titles and abstracts and excluded 739 citations at this stage, as
it was clear from the abstract that they would not be eligible for
inclusion. These included in vitro and animal studies, studies of
interventions other than liquid ventilation, studies not performed
in adults, review articles, commentaries and duplicate reports .
Of the remaining 10 articles, we excluded seven, as they were
not randomized controlled trials; one was excluded because it had
not yet been completed, and the remaining two were found to be
eligible for inclusion (Figure 1).
10Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome
(Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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Included studies
Two studies were eligible for inclusion in this updated review.
The first study (Hirschl 2002) was the only study included in
the original review because although the second study (Kacmarek
2006) had been completed at the time the original review was
conducted, the results were not published until 2006.
The study included in the original review (Hirschl 2002) was
a multi-centred RCT conducted between July 1995 and August
1996 at 18 centres in North America. This was a pilot study that
sought to evaluate the safety and efficacy of PLV in adults with
ARDS. The mean dose of PFC used was 22 mL/kg. As detailed
below (Characteristics of included studies), this study raised some
concerns related to changes in oxygenation criteria for recruitment
and the exclusion of patients with multiple organ failure, both of
which may influence the generalizabilty of results.
The additional study included in this review (Kacmarek 2006)
was a multi-centred RCT that was conducted at 56 centres in Eu-
rope and North America between December 1998 and December
2000. It enrolled 311 participants, achieving its target sample size,
although the sample size was changed on two occasions in response
to protocol amendments and interim analyses. Investigators eval-
uated two doses of PFC ’low dose’ of 10 mL/kg and ’high dose’
of 20 mL/kg using a control group that received CMV alone. All
three groups received standardized ventilatory support, target gas
exchange criteria for weaning were defined clearly a priori and the
numbers of weaning attempts per day were equal between groups
when these criteria were met and were not met. The study was
generally well conducted and was clearly reported. The long pe-
riod between the end of the study and publication of results, as
highlighted by the authors, emphasizes the problems associated
with publication of negative trials and the importance of negative
results to medical knowledge.
For both studies, participant follow-up appeared complete, and
no missing data were identified.
Neither of the included studies (Hirschl 2002 ;Kacmarek 2006)
addressed mortality beyond 28 d, duration of stay in intensive care
or of stay in hospital, morbidity, quality of life or cost-effectiveness.
Excluded studies
We excluded a total of seven completed studies from the review.
Details of these are provided in the Characteristics of excluded
studies table. Apart from one new included study (Kacmarek
2006), no new completed human adult studies in ARDS/ALI par-
ticipants of any design were identified in the new search (May
2004 toNovember 2012). Most reports on PLV were animal stud-
ies, review articles, letters or commentaries.
Risk of bias in included studies
We assessed risk of bias using the methods detailed above. We
have detailed the results in the Characteristics of included studies
section and have summarized them in Figure 2 and in Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.Other bias bias resulting from imbalance in baseline prognostic
variables and competing interests.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.Other bias bias resulting from imbalance in baseline prognostic variables and competing interests.
Allocation
In the study by Hirschl and colleagues (Hirschl 2002), the allo-
cation sequence was generated randomly, and a centralized inter-
vention assignment was used. These factors reduced the risk of
selection bias. However, participants randomly assigned to PLV
were randomly assigned on average 25 hours after other partici-
pants were randomly assigned to conventional ventilation. Those
in the PLV group therefore had a longer duration of mechanical
ventilation before randomization and may have been at a differ-
ent stage in their disease process compared with those in the con-
ventional ventilation group.The trial by Kacmarek and colleagues
(Kacmarek 2006) used a randomized computer method to gen-
erate the allocation sequence. Methods used to ensure allocation
concealment are not detailed in the trial report. The corresponding
author was contacted for clarification, but no further information
was obtained. However, given that a computer generated method
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of allocation was used, the overall risk of selection bias due to these
elements was judged to be low.
Blinding
Neither of the two included studies (Hirschl 2002; Kacmarek
2006) used blinding of participants or of key study personnel.
However, given that the outcome measures of both studies were
unambiguous and objective, the lack of blinding alone is unlikely
to have had a significant impact on outcome ascertainment. In the
study by Hirschl (Hirschl 2002), investigators did have access to
the interim data and were aware of the preliminary results. It was
on this basis that they decided to change the inclusion criteria.
Also although ventilation management guidelines were provided,
no measures were taken to ensure or to measure adherence to these
guidelines, and no guidelines were provided regarding the discon-
tinuation of PLV. It is therefore possible that participants may not
have been treated equally with respect to ventilation management,
weaning decisions and discontinuation of PLV.
Incomplete outcome data
The outcome data were assumed to be complete for both included
studies based on the fact that all enrolled participantswere followed
up in both studies. The study by Kacmarek (Kacmarek 2006)
provides a clear statement of follow-up: “311 patients who were
enrolled were followed up for the 28 day study period“. The trial
by Hirschl (Hirschl 2002) does not provide such a statement but
does provide enough information, based on adverse event data to
allow the reasonable assumption that all enrolled participants were
followed up for outcome assessment.
Selective reporting
No selective reporting bias was judged to be present in either of
the two included studies (Hirschl 2002; Kacmarek 2006).
Other potential sources of bias
The risk of bias from other sources was judged to be low in both
studies (Hirschl 2002; Kacmarek 2006).
Effects of interventions
See: Summary of findings for the main comparison
The two identified eligible studies addressed similar populations,
interventions and outcomes and were therefore reasonably clini-
cally homogenous.The trial by Kacmarek (Kacmarek 2006) em-
ployed two doses of PLV a higher dose of 20 mL/kg and a lower
dose of 10 mL/kg. Only the higher dose was used to calculate
pooled estimates of effect for the outcomes below, as the lower
dose was substantially less than the mean dose of 22 mL/kg used
in the trial by Hirschl (Hirschl 2002). Assessment of statistical
heterogeneity is limited by the small number of included studies,
but the CIs for all comparisons overlap, and I2 values were 0 and
20% for 28 mortality-free and ventilator-free days, respectively.
Mortality
The overall pooled estimate for the RR of mortality at 28 d of PLV
was 1.21 (95% CI 0.79 to 1.85, P = 0.37) (Figure 4) .
Figure 4. Forest plot of comparison 1. 28 day mortality, PLV versus CMV Outcome:28 Day Mortality.
Both included studies suggested a trend towards higher mortality
when PLV was used, but neither study showed a significant dif-
ference. Hirschl 2002 reported a 28 day mortality of 36% in the
CMV group and of 42% in the PLV group (RR of death with use
of PLV 1.15, P = 0.63). Kacmarek 2006 showed a 28 daymortality
of 15% in the CMV group compared with 26.3% in the low-dose
PLV group (RR 1.75, P = 0.06) and 19% in the high-dose PLV
group (RR 1.27, P = 0.39).
Duration of ventilation
’Days free of mechanical ventilation’ was used in both eligible trials
as ameasure of duration of ventilation. The overall pooled estimate
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of the effect of PLV on days free of mechanical ventilation at 28 d
was an MD of -2.24 (95% CI -4.71 to 0.23, P = 0.08) (Figure 5)
.
Figure 5. Forest plot of comparison 2.1. Ventilator-Free Days - PLV versus CMV - Outcome: Days Free of
Mechanical Ventilation at Day 28.
Hirschl 2002 did not show a significant difference in the num-
ber of days free from the ventilator at 28 d between those who
received PLV and those who received CMV (CMV = 6.7 d (stan-
dard deviation (SD) 9), PLV = 6.3 d (SD 8.06), MD -0.40, P =
0.85). Kacmarek 2006 showed significantly more days free from
the ventilator at 28 d in the CMV group than in the low-dose PLV
group (CMV = 13 d (SD 9.3), low dose PLV = 7.4 d (SD 8.5),
MD 5.6 d, P < 0.001) and in the high-dose PLV group (high-dose
PLV = 9.9 d (SD 9.1), MD 3.10, P = 0.043).Time to unassisted
ventilation was significantly shorter in the CMV group than in
both the low-dose PLV group (12.5 vs 18.9 days, MD 6.2 d, P
< 0.001) and the high-dose PLV group (12.5 vs 13.9 d, MD 1.4
days, P = 0.017). Also the percentage of participants alive and off
ventilation at 28 d was significantly greater in the CMV group
than in the low-dose PLV group (76% vs 53%, P < 0.001) or the
high-dose PLV group (76% vs 61%, P = 0.027).
Adverse events
Both studies reported data on the following adverse events: hy-
poxia, pneumothoraces, hypotension, bradycardia and cardiac ar-
rest. Pooled estimates of effect were calculated for each of these
outcomes. The RR of bradycardia in those who received PLV was
2.51 (95%CI 1.31 to 4.81, P = 0.005) (Figure 6). Pooled estimates
for other adverse events in those who received PLV were as follows:
hypoxia RR 1.77 (95% CI 0.97 to3.24, P = 0.06), pneumothorax
RR 2.06 (95% CI 0.71 to 5.95, P = 0.18), hypotension RR 1.38
(95% CI 0.87 to 2.18, P = 0.22), cardiac arrest RR 1.31 (95% CI
0.56 to 3.04, P = 0.54).
Figure 6. Forest plot of comparison 3.4. Adverse Events - Outcome: Bradycardia.
Both included studies reported high numbers of PLV-related ad-
verse events. Kacmarek reported statistically significantly more ad-
verse events in those receiving PLV (Kacmarek 2006) and noted
that most episodes of hypoxia and hypotension occurred during
the first five days of drug delivery; investigators attributed these
events to the need to interrupt ventilatory support to administer
the PFC. A similar observation was made by Hirsch, with most
adverse events occurring at the time of PFCdosing (Hirschl 2002).
Other outcomes
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Duration of respiratory support, duration of oxygen therapy,
length of stay in the ICU, length of stay in the hospital, infection
(sepsis, pneumonia), long-term cognitive impairment, long-term
health related quality of life, long-term lung function and costs
were not addressed by either trial.
D I S C U S S I O N
Summary of main results
Mortality
This review suggests a trend toward higher 28 day mortality with
the use of PLV versus CMV; however, the difference did not reach
statistical significance (RR 1.21, 95% CI 0.79 to 1.83, P = 0.37).
Duration of ventilation
Similarly, this review suggests a trend toward fewer ventilator-free
days when PLV versus CMV is used (MD 2.24 d, 95% CI 4.71
to - 0.23, P = 0.08).
Adverse events
Participants who received PLV were significantly more likely to
suffer bradycardia (RR 2.51, CI 1.31 to 4.81, P = 0.005), and
the pooled estimates of effect for other adverse events uniformly
suggested trends toward higher risk for those receiving PLV, but
these findings were not statistically significant.
Overall completeness and applicability of
evidence
The findings of this review are subject to the following important
limitations.
First, there is a lack of evidence. Only two studies were eligible for
inclusion in this review (Hirschl 2002; Kacmarek 2006).
Second, both studies used ventilator-free days as the primary end-
point. Ventilator-free days is a rather ambiguous concept thatwhen
used as a primary outcome measure carries an unacceptably high
risk of showing that a treatment that increases mortality is actually
superior (Schoenfeld 2002); it is an outcome of dubious clinical
relevance. Although 28 day mortality serves as a slightly more in-
formative outcome measure, it provides vital outcome informa-
tion only up to this limited time point. Neither study measured
morbidity, which is known to be substantial and persistent in sur-
vivors of ALI/ARDS (Herridge 2011). Unfortunately, the current
ongoing study of PLV in adults with ALI is assessing the oxygena-
tion index and pulmonary mechanics as primary outcome mea-
sures, with survival again reported as a secondary outcome mea-
sure (Chen 2011).
Third, this review used the AECC definition (Bernard 1994) of
ARDS to identify those used in the individual studies and in the
original review (Davies 2004). Both included studies excluded
patients with serious nonpulmonary organ dysfunction and severe
shock. Multiple-organ failure is the most common cause of death
in those who die with ALI; therefore, the findings of the included
studiesmay not be representative of patients with ARDS in general
(Stapleton 2005).
Finally, both studies preceded the era of lung protective ventila-
tion and used tidal volumes well in excess of 6 mL/kg (Hirschl
2002 used mean tidal volumes of 9 mL/kg actual body weight,
and Kacmarek 2006 used tidal volumes of 9 mL/kg predicted
bodyweight). Both the intervention groups and the control groups
received similar tidal volumes; therefore, it is unlikely that tidal
volume had a significant influence on the results of either study.
However, we cannot be sure what role if any PLV has when used
in accordance with ARDS Network guidelines (ARDS Network
2000).
Given the limitations detailed above, our findings should be
treatedwith caution. It is possible that additional research that uses
more participant-relevant outcomes, current definitions of ARDS
(The ARDSDefinition Task Force 2012) and lung protective ven-
tilation strategies may produce different results.
Quality of the evidence
The quality of both studies was reasonable in terms of risk of
bias; however, both studies were subject to the limitations detailed
above. Futhermore, both studies excluded patients with severe
nonpulmonary organ dysfunction, limiting the generalizabilty of
their results and hence of the results of this review .
Potential biases in the review process
Every effort was made to minimize selection and reporting bias by
comprehensively searching both mainstream and grey literature to
identify all relevant studies, with two review authors (IMG and
AS) separately applying a priori defined selection criteria to select
appropriate studies for inclusion.
The small number of eligible studies may contribute to content
bias. The findings of this review and meta-analysis need to be
interpreted in the light of these limitations.
Agreements and disagreements with other
studies or reviews
The findings of this review are consistent with those of existing
studies in humans, namely, that PLV has not been shown to of-
fer any survival benefit over CMV in participants with ALI and
ARDS. On the basis of results of the most recent human studies,
PLV in fact may be inferior to CMV, and it may be associated with
increased risk of adverse events (Kacmarek 2006;Hirschl 2002).
Several narrative reviews include sections on PLV, all of which ac-
knowledge that in the light of current evidence, this strategy can-
not be recommended in ALI/ARDS (Anzueto 2006; Lynch 2006).
The results of animal studies differ from those of human stud-
ies and of this review. Several animal models of ALI have shown
promising results in terms of improvements noted as reduced in-
16Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome
(Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
flammation and improved oxygenation and short-term survival
(Pakulla 2004; Zhu 2010). However, as is often the case, promis-
ing animal data do not necessarily translate into useful treatments
for humans.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
No evidence supports the use of PLV in adults with ALI or ARDS,
and some evidence suggests that PLV may be associated with in-
creased risk of adverse events.
Implications for research
Although no current evidence supports the use of PLV in practice,
available evidence is limited. Further clinical research may there-
fore be appropriate but would require very careful monitoring for
adverse events and would be most informative if it employed the
current definition of ARDS and lung protective ventilation strate-
gies, and if it addressed morbidity as well as mortality beyond 28
d.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Hirschl 2002
Methods Multi-centre, randomized controlled trial
Done between July 1995 and August 1996
Participants 90 participants with ALI/ARDS from 18 centres in the USA
Inclusion criteria:
• Bilateral infiltrates on CXR for ≤ 5 d;
• Mechanically ventilated for ≤ 5 d;
• FiO2 ≥ 0.5;
• PaO2/FiO2 ratio > 60 and < 300, irrespective of the level of positive end-
expiratory pressure; and
• Aged 15 to 75 y.
The first 45 participants were stratified according to Murray lung Injury score ≤ 2.5 or
> 2.5. They had their PaO2/FiO2 ratios determined at an FiO2 of 1
The second 45 participants also had to have an APACHE 2 score of < 30. They had
their PaO2/FiO2 ratios determined at an FiO2 of ≥ 0.5
Exclusion criteria:
• On ventilator support for diagnosed ALI/ARDS or with FiO2 > 0.4 for longer
than 24 h;
• On ventilator support for reasons other than diagnosed ALI/ARDS for longer
than three days in the previous 21 d;
• Tidal volume < 4 mL/kg;
• Neuromuscular respiratory failure or cardiac disease causing the compromise in
gas exchange;
• Lung parenchymal or airway surgery within 30 d of screening;
• Status asthmaticus or severe asthma currently under treatment with acute doses of
systemic corticosteroids, or severe chronic obstructive pulmonary disease requiring
long-term oxygen therapy;
• Systolic blood pressure < 90 mm Hg, which cannot be adequately maintained
with intravenous fluids and high-dose pressors;
• Intubation primarily for chronic interstitial lung disease (e.g., sarcoidosis,
idiopathic pulmonary fibrosis);
• Any active air leak from the lung into the pleural space;
• Seizures refractory to anticonvulsant therapy;
• High risk of mortality within three months of screening for reasons other than
ALI or ARDS or associated complications (e.g. terminal cancer with a high short-term
risk of mortality);
• Hypersensitivity to perfluorocarbons;
• Pregnant females;
• Receipt of any other experimental drug within 30 d of screening;
• Significant renal dysfunction defined by (1) serum creatinine > 3.0 mg/dL or (2)
an increase in serum creatinine of 0.8 mg/dL in 24 h;
• Significant hepatic dysfunction defined by serum total bilirubin > 2.0 mg/dL and
albumin < 2.5 g/dL; or a prothrombin time 3 s greater than control or > 1.5 times the
upper limit of normal and an activated partial thromboplastin time > 1.5 times the
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Hirschl 2002 (Continued)
upper limit of normal;
• Significant haematologic dysfunction defined by platelet count < 75,000/mm3 ; a
total white blood cell count < 1000/µL; or evidence of disseminated intravascular
coagulation; and
• In participants 46 to 90 y of age, high risk of mortality as defined by an APACHE
II score ≥ 30.
Interventions Randomly assigned to receive PLV or CMV for a maximum of four days for the first
45 participants and a maximum of five days for subsequent participants. Groups were
allocated at a PLV-to-CMV ratio of 2:1. Perflurocarbon was administered at a dosage
of 5 mL/kg increments based on ideal body weight to a maximum of 30 mL/kg. Each
participant was assessed every four hours for the presence of a meniscus visible within
the endotracheal tube during transient ventilator disconnect. If none was present, an
additional 1 to 5 mL/kg aliquot of perflubron was administered. PLV was discontinued
at the discretion of the investigator; no guidelines or rules regarding discontinuation of
PLV were provided
The mean duration of perflubron administration was 80 ± 3 h, with a range of 17 to
120 h
Outcomes Primary outcome:
• VFDs to day 28. The initial primary outcome was oxygenation, but this was
changed during the study to mean number of ventilator-free days to day 28. Ventilator-
free days to day 28 were defined as follows: “On Day 28, each survivor received 1 point
for every day following discontinuation of mechanical ventilation, including the day of
extubation, if the patient remained successfully weaned for the remainder of the day.
Participants who died during the first 28 d of the study received a VFD score of zero.
Participants who were re-intubated had days counted toward a VFD only if they
remained off the ventilator for the remainder of the 28-day period. For instance, if a
participant was extubated for two days and then re-intubated for the remainder of the
28 d, the VFD was zero. Only those days for which the participant was extubated and
remained extubated for the remainder of the 28-day experimental period counted
toward VFD”
Secondary outcomes included:
• 28 day mortality;
• PaO2/FiO2 ratio, A-a gradient; and
• lung mechanics.
Results: This study showed no difference in:
• number of ventilator-free days (CMV = 6.7 ± 1.8 d, PLV = 6.3 ± 1.0 d, P = 0.85);
• mortality at day 28 (CMV = 36%, PLV = 42%, P = 0.63); and
• any pulmonary-related parameter.
Adverse events:The authors donot provide P values or confidence intervals for all adverse
event outcomes but report higher incidence of adverse events in those receiving PLV
(99%) than in those receiving CMV (96%). Hypoxia, hypotension, pneumothoraces,
bradycardia, respiratory acidosis and cardiac arrest were all more common in the partial
liquid ventilation group
Other relevant outcomes that were not reported:
The following outcomes, which we consider clinically relevant, were not reported:
• Mortality (at discharge from ICU, at discharge from hospital and at one, two and
five years);
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Hirschl 2002 (Continued)
• Duration of mechanical ventilation;
• Duration of respiratory support;
• Duration of oxygen therapy;
• Length of stay in the ICU;
• Length of stay in hospital;
• Infection (septicaemia, pneumonia);
• Long-term cognitive impairment;
• Long-term health-related quality of life;
• Long-term lung function; and
• Cost.
Notes There are some concerns with this study regarding the following:
Methodological rigour and external validity:
Concerns regarding methodological rigour and generalizability of results due to changes
in selection criteria and primary endpoints during the course of the study and exclusion
of patients with refractory shock and renal, hepatic and haematological dysfunction
Adverse event reporting:
The authors conclude that “PLV may be performed reasonably safely in adult patients
with respiratory failure with few adverse events, which appear to be transient, self limited
and with appropriate vigilance, manageable”. This statement does not accurately repre-
sent the findings of the study, which showed a higher incidence of hypoxia, hypotension,
pneumothoraces, bradycardia and cardiac arrest in the partial liquid ventilation group,
most of which occurred at times of perfluorocarbon dosing, and at least four episodes of
cardiac arrest were attributable to treatment in this group
Miscellaneous:
A large number of post hoc analyses are reported. Post hoc analyses showed more rapid
discontinuation of ventilation in the PLV arm (P = 0.045), although participants who
were randomly assigned to PLV had a longer length of CMV before randomization (P =
0.12). The time lag involved may explain the difference in rapidity of discontinuation,
as those randomly assigned later may already be in the recovery phase of their illness
18 centres were involved, although only 4 centres enrolled more than 5 participants of
the total 90 participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomizationwas performed ac-
cording to a 2 or 6 block design ...“
Comment: Probably done, as although the
authors do not tell us the exact method of
randomization used, they do tell us that
randomization was performed
Allocation concealment (selection bias) Low risk Quote: “After granting of informed con-
sent, a central office at Alliance Pharmaceu-
tical was contacted for group assignment”
Comment: Probably done, as a centralized
randomization process is described
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Hirschl 2002 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Quotes:“This was a prospective, non
blinded, randomized study…”
”After entry of 45 patients evaluation of the
data suggested a trend ....“
”No monitoring committee was used“
”There was no follow up to ensure that
investigators adhered to these (ventilation)
guidelines“
Comment: Not done, as the authors clearly
state from the outset that no blinding
was employed. The outcome measures ad-
dressed ’ventilator free days’, ’28 day mor-
tality’ and ’physiological indices’ were ob-
jective and therefore were unlikely to be in-
fluenced by the lack of blinding. However,
the fact that at least some of the investiga-
tors had access to unblinded interim data,
together with the lack of any method of en-
suring or measuring adherence to ventila-
tion guidelines, raise concerns over possible
performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk There was no blinding of outcome mea-
sures, but the outcomes addressed were un-
ambiguous and therefore were unlikely to
be influenced significantly by the lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk The authors enrolled 90 participants but
do not provide a statement of completeness
of follow-up or any details of losses to fol-
low-up. Results for primary and secondary
outcomes are not presented in a way that
allows the reader to determine whether all
participants were followed up for the dura-
tion of the study
However, adverse event data are presented
in terms of absolute numbers, and for each
event, these numbers add up to 90, so it
is likely that all included participants were
followed up for outcome
Selective reporting (reporting bias) Unclear risk Quotes: “No significant difference in the
number of days free from ventilation at 28
days, the incidence of mortality or any pul-
monary related parameter was noted”
“PLV may be performed safely in adult pa-
tients with respiratory failure with few ad-
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Hirschl 2002 (Continued)
verse events, which appear to be transient,
self limited and, with appropriate vigilance,
manageable“
Comments: The authors provide unbiased
reports for the primary and secondary out-
come measures of ventilator-free days and
28 day mortality. Both of these are clearly
defined in the methods section of the re-
port, and both are reported in an unbiased
way
However, the severity, seriousness and sig-
nificance of adverse events are under-appre-
ciated and under-reported
Other bias Low risk Participants randomly assigned to the PLV
group were randomly assigned an average
of 25 h later than those who were randomly
assigned to the CMV group
However, this baseline imbalance in pre-
randomization of duration of ventilation is
unlikely to have resulted in significant bias
Kacmarek 2006
Methods Prospective, multi-centre, randomized controlled trial
Done between December 1998 and December 2000
Participants 311 participants with ARDS from 56 centres in North America and Europe
Inclusion criteria:
• Risk factor for ALI/ARDS;
• Prior mechanical ventilation for 120 h or less;
• Acute, bilateral infiltrates on chest radiograph; and
• PaO2/FiO2 of 200 mm Hg or less with an FiO2 of 0.5 or greater and PEEP of 5
cm H2O or greater.
Exclusion criteria:
• Age younger than 16 or older than 65 y;
• Acute Physiology and Chronic Health Evaluation (APACHE) II score ≥ 30;
• Longer than 48 h since meeting inclusion criteria;
• Inability to obtain informed consent;
• Significant nonpulmonary organ dysfunction as defined by the following:
◦ Chronic renal failure requiring dialysis;
◦ Acute liver disease with significant hepatocellular or cholestatic liver injury
(acute hepatitis or acute cholestasis);
◦ Severe chronic liver disease (bilirubin > 3 mg/dL and serum albumin > 3 g/
dL); or
◦ Haematological dysfunction, defined by a total polymorphonuclear
leukocyte (PMN) count < 0 .5 × 103/mL.
• Systolic blood pressure < 90 mm Hg, unresponsive to treatment with fluids and
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Kacmarek 2006 (Continued)
vasopressors;
• Congestive heart failure, defined by a pulmonary arterial occlusion pressure >18
mm Hg or by clinical examination;
• Clinical history of decompensated left ventricular dysfunction as indicated by
New York Heart Association Class III or IV or left ventricular ejection fraction < 30%;
• Documented myocardial infarction within the previous three months; or life-
threatening arrhythmia during the present hospital admission;
• Glasgow Coma Score < 10 determined before administration of confounding
medications, such as narcotics, sedatives or neuromuscular blockers;
• Active air leak from the lung into the pleural space in the 24 h before
randomization (chest tube to pleura vac with water seal without leak and not requiring
suction for a minimum of 24 h was allowed);
• Evidence of increased intracranial pressure or history of an intracerebral
haemorrhage within the previous three months;
• Status asthmaticus or severe asthma currently under treatment with
pharmacological doses of intravenous corticosteroids;
• Chronic lung disease requiring long-term oxygen therapy or presenting with a
baseline FEV1 < 700 mL;
• Spinal cord injury above T-1;
• Myasthenia gravis or Guillain-Barre´ syndrome or other neurological disorder
that impairs the patient’s ability to breath spontaneously;
• Organ transplantation (i.e. bone marrow, heart, lung, liver, kidney, pancreas);
• Seizures refractory to anticonvulsant therapy;
• Acute parenchymal lung injury secondary to suspected overdose of narcotics;
• Burn injury (2nd or 3rd degree) with greater than 30% of total body surface area
or with a restrictive chest injury;
• Life expectancy of < 3 months for other than ALI/ARDS-associated
complications;
• Positive blood test for HIV with CD-4 count < 200;
• Received chemotherapy within 30 d before enrolment;
• Morbid obesity (more than twice ideal body weight);
• Tracheostomy;
• Vascular lung disease with alveolar haemorrhage or pulmonary hypertension;
• Hypersensivity to perfluorocarbons;
• Positive serum β-human chorionic gonadotropin (HCG) indicating pregnancy;
and
• Received any other experimental treatment within 30 d before screening (except
nitric oxide, provided nitric oxide had been discontinued at least 4 h before initiation
of standardized mechanical ventilation).
Interventions Randomly assigned to receive:
• Conventional mechanical ventilation;
• Low-dose partial liquid ventilation
instillation of PFC into the lungs to the level of the carina at zero-PEEP; or
• High-dose partial liquid ventilation
instillation of PFC into the lungs to an ETT level 5 cm below the incisors at zero-
PEEP.
Five participants did not receive the intended intervention (two randomly assigned to
low-dose PLV and three randomly assigned to high-dose PLV never received PLV).
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Kacmarek 2006 (Continued)
However, analysis was performed on the basis of ’intention to treat’
Outcomes Primary outcome:
• Ventilator-free days during the 28 dafter randomization, with a ventilator-free day
defined as any day between randomization and 28 d post-randomization when the
participant was not ventilated and sustained unassisted breathing for three or more
consecutive days. Participants who died or required extracorporeal oxygenation during
this period received no ventilator-free days. Participants who were re-intubated after
extubation failure received ventilator-free days only from the time following final
extubation.
Secondary outcomes:
• All-cause 28 day mortality;
• Time to unassisted ventilation;
• Percentage of participants alive and off ventilation at Day 28;
• Time to ARDS resolution defined as the time to a PaO2/FiO2 of 200 mm Hg or
greater with a PEEP of 5 cm H2O or less and an FiO2 of 0.5 or less; and
• Arterial blood gases, ventilator, physiological, laboratory and radiographic data
obtained after stabilization on standardized ventilator settings at 12, 24, 48, 72, 96 and
120 h, and at 7, 14 and 28 d after randomization.
Results: This study reported:
• More ventilator-free days in the CMV group (13.0 ± 9.3) than in both the low-
dose PLV group (7.4 ± 8.5 d, P < 0.001) and the high-dose PLV group (9.9 ± 9.1 d; P
= 0.043);
• 28-Day mortality in the CMV group was only 15.0% versus 26.3% in the low-
dose PLV group (P = 0.06) and 19.1% in the high-dose PLV group (P = 0.39);
• Time to unassisted ventilation was shorter (12.5 vs 18.9 d, P < 0.001) in the
CMV group than in the low-dose PLV group and in the high-dose PLV group (12.5 vs
13.9 d, P = 0.017);
• Percentage of participants alive and off ventilation at 28 d was greater in the
CMV group than in the low-dose PLV group (76 vs 53, P < 0.001) and in the high-
dose PLV group (76 vs 61, P = 0.027); and
• Time to resolution of ARDS/ALI was significantly faster in the CMV group than
in the low-dose PLV group (12.5 vs 18.9 d, P < 0.001) and was faster in the CMV
group than in the high-dose PLV group (10 vs 10.6 d, P = 0.12).
Adverse events:
Statistically significantly (P < 0.05) more episodes of pneumothoraces, hypoxia and
hypotension in PLV groups than in the CMV group. The authors state that most of
the hypoxic and hypotensive events in the PLV group occurred during the first 5 d of
drug delivery and were associated with initial and subsequent filling of the lungs with
perfluorocarbon. They attributed this to the need to interrupt ventilator support to
administer the perfluorocarbon
Other relevant outcomes that were not reported:
The following outcomes, which we considered clinically relevant, were not reported:
• Mortality (at discharge from ICU, at discharge from hospital and at one, two and
five years);
• Duration of oxygen therapy;
• Length of stay in the ICU;
• Length of stay in the hospital;
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• Infection (septicaemia, pneumonia);
• Long-term cognitive impairment;
• Long-term health-related quality of life;
• Long-term lung function; and
• Cost.
Notes Although the study was generally well conducted and well reported, there are some
concerns regarding the following:
Internal validity:
Investigators changed the target sample size on two occasions in response to protocol
amendments and interim analyses, and the rationale for these changes is not well ex-
plained or justified
Initially a total sample size of 480 was estimated for a power of ≥ 90% for a two-sided t
test, to detect a 3VFDdifference between groupswith an overall type 1 error of 5%. After
protocol amendments, this was decreased to 260, and the number of VFD considered to
represent a significant difference was increased from three to four. After interim analysis,
the sample size was subsequently increased to 309 with a power of 80% for a two-sided
t test to detect a 4 VFD difference between groups with an overall type 1 error of 5%
External validity:
This study excluded patients with shock and severe nonpulmonary organ dysfunction,
and the strict oxygenation criteria for inclusion meant that only those with severe lung
injury were included. This limits its generalizability to a subset of critically ill patients
with severe lung injury without multiple organ dysfunction
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly assigned
to one of 4 groups...Group assignment was
performed using a computerized random-
ization system”
Comment: Probably done, as the investi-
gators describe a random method
Allocation concealment (selection bias) Low risk Quote:“Group assignment was performed
using a computerized randomization sys-
tem.”
Comment: Probably done, as the investi-
gators describe a random method
Blinding (performance bias and detection
bias)
All outcomes
Low risk No blinding of participants or personnel
is described, but evidence for equal treat-
ment of the two groups with respect to an-
cillary treatment comes from the fact that
both groups received standardized ventila-
tory support, target gas exchange criteria
for weaning were defined a priori and the
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Kacmarek 2006 (Continued)
number of weaning attempts per day was
equal between the groups when these cri-
teria were met and were not met
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding of outcome assessment is de-
scribed, but the objective nature of the out-
come measures used (i.e. ‘ventilator free
days’, ‘time to unassisted ventilation’, ‘time
to resolution of ARDS’, ‘percentage of pa-
tients alive and off ventilation at 28 days’
and ‘28 day mortality’) means that this is
unlikely to result in significant bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “311 patients who were enrolled
were followed up for the 28 day study pe-
riod“
Comment: Probably done, as all enrolled
participants were followed up for the study
period, and outcome datawere reported for
all enrolled participants
Selective reporting (reporting bias) Low risk Quote “The primary outcome was ventila-
tor free days during the 28 days following
randomization. The secondary outcomes
were mortality, time to unassisted ventila-
tion ….“
Comment: Study protocol is not available,
but the primary and secondary outcomes as
reported are clearly stated in the methods
section of the report
Other bias Low risk
• A-a = alveolar-arterial.
• ALI = acute lung injury.
• APACHE = acute physiology and chronic health evaluation system.
• ARDS = acute respiratory distress syndrome.
• CMV = conventional mechanical ventilation.
• CXR = chest x-ray.
• d = days.
• ETT = endotracheal tube.
• FiO2 = fraction of inspired oxygen.
• ICU = intensive care unit.
• PaO2 = arterial oxygen tension.
• PEEP = positive end-expiratory pressure.
• PFC = perfluorocarbon liquid.
• PLV = partial liquid ventilation.
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• Ppc,we = pulmonary capillary wedge pressure.
• s = seconds.
• VFD = ventilator-free days.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Hirschl 1995 Case series
Not randomized
No control group
Hirschl 1996 Not randomized
No control group
Hirschl 1998 Not randomized
No control group
Kazerooni 1996 Not randomized
No control group
Meaney 1997 Case series
Not randomized
No control group
Reickert 2001 Not randomized
No control group
Schuster 2001 This study compared chest radiograph filling patterns in participants with acute lung injury who had received low-
dose (10 mL/kg) or high-dose perflubron (20ml/kg). There was no control group that did not receive perflubon
Characteristics of ongoing studies [ordered by study ID]
Chen 2011
Trial name or title Perfluorocarbon (PFC) Inhalation Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome
Methods Randomized controlled single-blind trial with cross-over assignment
Participants Mechanically ventilated adults with acute lung injury
Interventions Experimental: Perfluorocarbon Placebo Comparator: Sterile Water for Injection
Outcomes Primary outcome measures: oxygenation index, respiratory mechanics
Secondary outcome measures: 3-y survival, ventilator-free days, 28-d mortality
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Chen 2011 (Continued)
Starting date August 2011
Contact information Contact: Zhixin Liang, MD
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. 28 day mortality - PLV versus CMV
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 28 Day Mortality 2 302 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.79, 1.85]
Comparison 2. Ventilator Free Days - PLV versus CMV
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Days Free of Mechanical
Ventilation at Day 28
2 302 Mean Difference (IV, Random, 95% CI) -2.24 [-4.71, 0.23]
Comparison 3. Adverse Events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hypoxia 2 302 Risk Ratio (M-H, Random, 95% CI) 1.77 [0.97, 3.24]
2 Pneumothorax 2 302 Risk Ratio (M-H, Random, 95% CI) 2.06 [0.71, 5.95]
3 Hypotension 2 302 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.87, 2.19]
4 Bradycardia 2 302 Risk Ratio (M-H, Random, 95% CI) 2.51 [1.31, 4.81]
5 Cardiac Arrest 2 302 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.56, 3.04]
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Analysis 1.1. Comparison 1 28 day mortality - PLV versus CMV, Outcome 1 28 Day Mortality.
Review: Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome
Comparison: 1 28 day mortality - PLV versus CMV
Outcome: 1 28 Day Mortality
Study or subgroup PLV CMV Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hirschl 2002 27/65 9/25 50.2 % 1.15 [ 0.64, 2.10 ]
Kacmarek 2006 20/105 16/107 49.8 % 1.27 [ 0.70, 2.32 ]
Total (95% CI) 170 132 100.0 % 1.21 [ 0.79, 1.85 ]
Total events: 47 (PLV), 25 (CMV)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PLV Favours CMV
Analysis 2.1. Comparison 2 Ventilator Free Days - PLV versus CMV, Outcome 1 Days Free of Mechanical
Ventilation at Day 28.
Review: Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome
Comparison: 2 Ventilator Free Days - PLV versus CMV
Outcome: 1 Days Free of Mechanical Ventilation at Day 28
Study or subgroup PLV CMV
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hirschl 2002 65 6.3 (8.06) 25 6.7 (9) 31.9 % -0.40 [ -4.44, 3.64 ]
Kacmarek 2006 105 9.9 (9.1) 107 13 (9.3) 68.1 % -3.10 [ -5.58, -0.62 ]
Total (95% CI) 170 132 100.0 % -2.24 [ -4.71, 0.23 ]
Heterogeneity: Tau2 = 0.73; Chi2 = 1.25, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours CMV Favours PLV
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Analysis 3.1. Comparison 3 Adverse Events, Outcome 1 Hypoxia.
Review: Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome
Comparison: 3 Adverse Events
Outcome: 1 Hypoxia
Study or subgroup PLV CMV Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hirschl 2002 37/65 11/25 48.2 % 1.29 [ 0.79, 2.11 ]
Kacmarek 2006 49/105 21/107 51.8 % 2.38 [ 1.54, 3.67 ]
Total (95% CI) 170 132 100.0 % 1.77 [ 0.97, 3.24 ]
Total events: 86 (PLV), 32 (CMV)
Heterogeneity: Tau2 = 0.13; Chi2 = 3.40, df = 1 (P = 0.07); I2 =71%
Test for overall effect: Z = 1.86 (P = 0.063)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PLV Favours CMV
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Analysis 3.2. Comparison 3 Adverse Events, Outcome 2 Pneumothorax.
Review: Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome
Comparison: 3 Adverse Events
Outcome: 2 Pneumothorax
Study or subgroup PLV CMV Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hirschl 2002 15/65 5/25 46.4 % 1.15 [ 0.47, 2.84 ]
Kacmarek 2006 30/105 9/107 53.6 % 3.40 [ 1.70, 6.80 ]
Total (95% CI) 170 132 100.0 % 2.06 [ 0.71, 5.95 ]
Total events: 45 (PLV), 14 (CMV)
Heterogeneity: Tau2 = 0.42; Chi2 = 3.50, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PLV Favours CMV
Analysis 3.3. Comparison 3 Adverse Events, Outcome 3 Hypotension.
Review: Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome
Comparison: 3 Adverse Events
Outcome: 3 Hypotension
Study or subgroup PLV CMV Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hirschl 2002 28/65 10/25 46.5 % 1.08 [ 0.62, 1.88 ]
Kacmarek 2006 32/105 19/107 53.5 % 1.72 [ 1.04, 2.83 ]
Total (95% CI) 170 132 100.0 % 1.38 [ 0.87, 2.19 ]
Total events: 60 (PLV), 29 (CMV)
Heterogeneity: Tau2 = 0.04; Chi2 = 1.52, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 1.38 (P = 0.17)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PLV Favours CMV
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Analysis 3.4. Comparison 3 Adverse Events, Outcome 4 Bradycardia.
Review: Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome
Comparison: 3 Adverse Events
Outcome: 4 Bradycardia
Study or subgroup PLV CMV Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hirschl 2002 16/65 2/25 21.6 % 3.08 [ 0.76, 12.42 ]
Kacmarek 2006 21/105 9/107 78.4 % 2.38 [ 1.14, 4.95 ]
Total (95% CI) 170 132 100.0 % 2.51 [ 1.31, 4.81 ]
Total events: 37 (PLV), 11 (CMV)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.78 (P = 0.0054)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PLV Favours CMV
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Analysis 3.5. Comparison 3 Adverse Events, Outcome 5 Cardiac Arrest.
Review: Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome
Comparison: 3 Adverse Events
Outcome: 5 Cardiac Arrest
Study or subgroup PLV CMV Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hirschl 2002 15/65 4/25 71.3 % 1.44 [ 0.53, 3.93 ]
Kacmarek 2006 3/105 3/107 28.7 % 1.02 [ 0.21, 4.94 ]
Total (95% CI) 170 132 100.0 % 1.31 [ 0.56, 3.04 ]
Total events: 18 (PLV), 7 (CMV)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours PLV Favours CMV
A P P E N D I C E S
Appendix 1. Search strategy for CENTRAL, The Cochrane Library
#1 MeSH descriptor Respiratory Distress Syndrome, Adult explode all trees
#2 MeSH descriptor Acute Lung Injury explode all trees
#3 ALI or ARDS or acute lung injury
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Liquid Ventilation explode all trees
#6 MeSH descriptor Fluorocarbons explode all trees
#7 ventilation
#8 (#5 OR #6 OR #7)
#9 (#4 AND #8)
Appendix 2. Search strategy for MEDLINE (Ovid SP)
1. exp RESPIRATORY DISTRESS SYNDROME, ADULT/ or exp Acute Lung Injury/ or (ALI or ARDS or acute lung injury).mp.
2. exp FLUOROCARBONS/ or exp Liquid Ventilation/ or fluorocarbon*.af. or (liquid adj3 ventilation).mp.
3. 1 and 2
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Appendix 3. Search strategy for EMBASE (Ovid SP)
1. exp respiratory-distress-syndrome/ or exp respiratory-distress/ or exp acute-lung-injury/ or (ARDS or ALI or (acute adj3 lung
injur*)).mp.
2. exp fluorocarbon-/ or exp liquid-ventilation/ or fluorocarbon*.af. or (liquid adj3 ventilation).mp.
3. 1 and 2
Appendix 4. Search strategy for CINAHL (EBSCO host)
S1 ((MM ”Respiratory Distress Syndrome, Acute“) OR (MM ”Respiratory Distress Syndrome+“) OR (MM ”Acute Lung Injury+“) )
OR TX ( ALI or ARDS or acute lung injury )
S2 ( (MM ”Fluorocarbons“) OR (MM ”Ventilation, Liquid“) ) OR TX fluorocarbon* OR TX liquid ventilation
S3 S1 and S2
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Date Event Description
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H I S T O R Y
Protocol first published: Issue 3, 2002
Review first published: Issue 4, 2004
Date Event Description
10 July 2013 New citation required and conclusions have changed This update was conducted by four new team members
(IMG, AS, NDF, RP) working together with one of the
original review authors (MWD)
The findings of this updated review differed slightly from
those of the original review (Davies 2004) in that previously
no evidencewas found to support or refute the role of partial
liquid ventilation in adults with ALI/ARDS; new evidence
suggests that it is not superior to conventional mechanical
ventilation and may be associated with a higher incidence
of adverse events
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(Continued)
10 July 2013 New search has been performed This review is an update of a previous Cochrane systematic
review of the same title (Davies 2004) that included only
one study. The literature search for this current version
was extended from May 2004 to November 2012, with
preservation of the original criteria for study inclusion and
review objectives. The abstract, background, plain language
summary, methods, results and discussion sections were
rewritten to take account of relevant new information on
acute lung injury and partial liquid ventilation and current
guidance for the completion of Cochrane reviews (Higgins
2011). Risk of bias assessment with tables and figures was
included
One new eligible study was identified and included (
Kacmarek 2006), yielding a total of two eligible studies.
Pooled estimates of effect of partial liquid ventilation on
mortality, days free of mechanical ventilation at 28 days
and adverse events were calculated
2 August 2008 Amended Converted to new review format.
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We rewrote the abstract, background, plain language summary, methods, results and discussion sections to take account of relevant new
information on acute lung injury and partial liquid ventilation and current guidance for the completion of Cochrane reviews (Higgins
2011). We included risk of bias assessment with tables and figures.
This updated version was conducted by four new team members (IMG, AS, NDF, RP) working together with one of the original
authors (MWD).
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Lung Injury [mortality; ∗therapy]; LiquidVentilation [∗methods];Morbidity; RandomizedControlledTrials asTopic; Respiratory
Distress Syndrome, Adult [mortality; ∗therapy]
MeSH check words
Adult; Humans
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